Journal article
Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease
Abstract
BACKGROUND: Apixaban is superior to aspirin for the prevention of stroke in patients with atrial fibrillation. Apixaban is partially renally excreted and may accumulate in patients with renal impairment.
METHODS: We evaluated the efficacy and safety of apixaban 5 mg twice daily (2.5 mg twice daily in selected patients) compared with aspirin 81 to 324 mg daily in 1697 patients with stage III chronic kidney disease (CKD) enrolled in the Apixaban …
Authors
Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O’Donnell M; Yusuf S; Hart RG
Journal
Journal of Stroke and Cerebrovascular Diseases, Vol. 21, No. 6, pp. 429–435
Publisher
Elsevier
Publication Date
August 2012
DOI
10.1016/j.jstrokecerebrovasdis.2012.05.007
ISSN
1052-3057
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAspirinAtrial FibrillationBiomarkersChi-Square DistributionCreatinineDouble-Blind MethodEmbolismFemaleFibrinolytic AgentsGlomerular Filtration RateHemorrhageHumansKidneyMaleProportional Hazards ModelsPyrazolesPyridonesRenal Insufficiency, ChronicRisk AssessmentRisk FactorsSeverity of Illness IndexStrokeTreatment Outcome